Mikhail Blagosklonny teaches at the Roswell Park Cancer Institute in Buffalo, NY as a professor in the oncology department. His areas of study are cancer and aging. He graduated with an M.D. in internal medicine and a Ph. D. in cardiology and experimental medicine from the First Pavlov State Medical University of St. Peterburg, Russia. In 2002, Dr. Blagosklonny became the associate professor of medicine at the New York Medical College in Valhalla, NY. Later, he accepted a position at the Ordway Research Institute in Albany, NY as a senior scientist and remained in this position until 2009 when he moved on to work for the Roswell Park Cancer Institute.
At the Roswell Park Cancer Institute, Dr. Blagosklonny studies cancer, cancer therapies, aging, biogerontology (the study of the underlying mechanisms causing aging) and anti-aging drugs. He researches cancer therapies intended to target only cancer cells, protecting the healthy cells from damage. Dr. Blagosklonny developed a hypothesis concerning TOR Signaling playing a role in cancer and aging. He recommended using Rapamycin, a popular cancer drug, as a life extension treatment in older patients. He is one of the most zealous advocates of using Rapamycin for longevity.
Dr. Blagosklonny is the editor-in-chief for the publications “Oncotarget”, “Cell Cycle” and “Aging”. He is also an editor of “Cancer Biology & Therapy” and “Cell Death & Differentiation.”
Mikhail Blagosklonny believes that cancer can be cured and that aging can be controlled. Mikhail has dedicated his life to oncology research, driven by his love for humanity and hope for a disease-free world. Visit ResearchGate.Net to learn more about Mikhail’s latest work.